TickerFacts.

BioCryst Pharmaceuticals Inc (BCRX): R&D Expense

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2012-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$166.13M
Year ended 2025-12-31
$197.76M
Trailing 12 months to 2026-06-30
-13.1%
3-year compound annual growth
+6.2%
5-year compound annual growth
+8.6%
10-year compound annual growth
$253.30M2009-12-31: $73.66M2010-12-31: $83.90M2011-12-31: $57.25M2012-12-31: $49.16M2013-12-31: $41.94M2014-12-31: $51.80M2015-12-31: $72.76M2016-12-31: $61.01M2017-12-31: $66.96M2018-12-31: $84.89M2019-12-31: $107.07M2020-12-31: $122.96M2021-12-31: $208.81M2022-12-31: $253.30M2023-12-31: $216.57M2024-12-31: $174.64M2025-12-31: $166.13M$166.13M
2009-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$166.13M-4.9%2026-02-26, From 2025-01-01
2024-12-31$174.64M-19.4%2026-02-26, From 2024-01-01
2023-12-31$216.57M-14.5%2026-02-26, From 2023-01-01
2022-12-31$253.30M+21.3%2025-02-25, From 2022-01-01
2021-12-31$208.81M+69.8%2024-02-27, From 2021-01-01
2020-12-31$122.96M+14.8%2023-02-27, From 2020-01-01
2019-12-31$107.07M+26.1%2022-02-28, From 2019-01-01
2018-12-31$84.89M+26.8%2021-03-01, From 2018-01-01
2017-12-31$66.96M+9.8%2020-03-13, From 2017-01-01
2016-12-31$61.01M-16.1%2019-03-14, From 2016-01-01
2015-12-31$72.76M+40.5%2018-03-12, From 2015-01-01
2014-12-31$51.80M+23.5%2017-02-27, From 2014-01-01
2013-12-31$41.94M-14.7%2016-02-26, From 2013-01-01
2012-12-31$49.16Mn/c2015-03-02, From 2012-01-01
2011-12-31$57.25M-31.8%2014-03-10, From 2011-01-01
2010-12-31$83.90M+13.9%2013-03-11, From 2010-01-01
2009-12-31$73.66Mn/a2012-03-06, From 2009-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
BioCryst Pharmaceuticals Inc (BCRX)2025-12-31$166.13M-4.9%
Repligen Corp (RGEN)2025-12-31$54.18M+25.4%
Novavax Inc (NVAX)2025-12-31$342.32M-12.5%
Bio-Techne Corp (TECH)2026-06-30$94.77M-4.8%
Halozyme Therapeutics, Inc. (HALO)2025-12-31$81.49M+3.1%
ADMA Biologics, Inc. (ADMA)2025-12-31$4.76M+162.7%
Tarsus Pharmaceuticals, Inc. (TARS)2025-12-31$64.32M+20.5%
Immunocore Holdings plc (IMCR)2025-12-31$274.87M+23.7%
Moderna, Inc. (MRNA)2025-12-31$3.13B-31.1%

Compare BCRX, RGEN, NVAX, TECH side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗